| scholarly article | Q13442814 |
| P50 | author | Peng Wei | Q47100630 |
| Theodosia A. Kalfa | Q47100638 | ||
| Russell E Ware | Q56785312 | ||
| Barry R. Davis | Q64684716 | ||
| Janet L Kwiatkowski | Q89645734 | ||
| P2093 | author name string | John Wood | |
| William Owen | |||
| Abdullah Kutlar | |||
| Robert J Adams | |||
| Kathleen J Helton | |||
| Alan R Cohen | |||
| Naomi L C Luban | |||
| Margaret T Lee | |||
| Lori Luchtman-Jones | |||
| Judy Luden | |||
| R Clark Brown | |||
| Scott T Miller | |||
| Zora R Rogers | |||
| Sara Pressel | |||
| Stephen Nelson | |||
| Matthew M Heeney | |||
| Alexis A Thompson | |||
| Banu Aygun | |||
| Beng Fuh | |||
| Ofelia Alvarez | |||
| Alex George | |||
| Nicole A Mortier | |||
| William H Schultz | |||
| Isaac Odame | |||
| Melissa Rhodes | |||
| Hamayun Imran | |||
| Sharada Sarnaik | |||
| Jennifer A Rothman | |||
| Melanie J Bonner | |||
| Cynthia Gauger | |||
| Connie Piccone | |||
| Niren Patel | |||
| Lee Hilliard | |||
| Donna Roberts | |||
| Linda Piller | |||
| Kerri Nottage | |||
| Jamie Coleman | |||
| Sherron Jackson | |||
| Carla Roberts | |||
| Susan E Stuber | |||
| P2860 | cites work | Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members | Q30459060 |
| Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial | Q30830149 | ||
| Intra-individual variation in blood flow velocities in cerebral arteries of children with sickle cell disease | Q33841486 | ||
| How I use hydroxyurea to treat young patients with sickle cell anemia | Q33985120 | ||
| Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia | Q34308407 | ||
| Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia | Q34330904 | ||
| Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease | Q34557931 | ||
| Genetic predictors for stroke in children with sickle cell anemia | Q35067635 | ||
| Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). | Q35097294 | ||
| Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload | Q35209572 | ||
| Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease | Q36011461 | ||
| Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload | Q36244031 | ||
| Developmental function in toddlers with sickle cell anemia | Q36568784 | ||
| Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia | Q36779445 | ||
| Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia | Q36788867 | ||
| Optimizing hydroxyurea therapy for sickle cell anemia | Q38935184 | ||
| Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. | Q40895215 | ||
| Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload | Q42744561 | ||
| A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality | Q43640748 | ||
| Hydroxyurea for children with sickle cell disease | Q43723380 | ||
| Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort | Q44448652 | ||
| Physician attitude, awareness, and knowledge regarding guidelines for transcranial Doppler screening in sickle cell disease | Q44577637 | ||
| Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy | Q45041402 | ||
| Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. | Q45190220 | ||
| Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography | Q47906551 | ||
| Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. | Q53391834 | ||
| The use of transcranial ultrasonography to predict stroke in sickle cell disease. | Q55043495 | ||
| Computations for group sequential boundaries using the Lan-DeMets spending function method | Q73816032 | ||
| Cerebrovascular accidents in sickle cell disease: rates and risk factors | Q73982009 | ||
| Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease | Q82106694 | ||
| P433 | issue | 10019 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | transcranial Doppler | Q3512319 |
| hydroxycarbamide | Q212272 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 661-670 | |
| P577 | publication date | 2015-12-04 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority tria | |
| P478 | volume | 387 |
| Q40038732 | A Clinically Meaningful Fetal Hemoglobin Threshold for Children with Sickle Cell Anemia During Hydroxyurea Therapy. |
| Q92518138 | A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study |
| Q88440631 | A Retrospective Analysis of Sociodemographic and Hematologic Characteristics Associated With Achieving Optimal Hydroxyurea Therapy in Children With Sickle Cell Disease |
| Q96764325 | Advances in Sickle Cell Disease Management |
| Q64949463 | Advances in new drug therapies for the management of sickle cell disease. |
| Q48249605 | An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes. |
| Q88101760 | Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea |
| Q24202463 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease |
| Q36251052 | Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. |
| Q92417751 | Brain O2 reserve in sickle cell disease |
| Q56243473 | Cancer incidence in a cohort of asbestos-exposed workers undergoing health surveillance |
| Q38898163 | Cellular therapy for sickle cell disease |
| Q50420228 | Children with sickle cell anemia with normal TCD and without silent infarcts have a low incidence of new strokes. |
| Q91616633 | Chronic transfusion therapy effectiveness as primary stroke prophylaxis in sickle cell disease patients |
| Q50061141 | Clinical Features of β-Thalassemia and Sickle Cell Disease |
| Q38619234 | Clinical risks and healthcare utilization of haematopoietic cell transplantation for sickle cell disease in the U.S. using merged databases |
| Q33552132 | Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project |
| Q64885599 | Current challenges in the management of patients with sickle cell disease - A report of the Italian experience. |
| Q37285132 | EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. |
| Q33726299 | Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country. |
| Q91757352 | End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain |
| Q38985177 | Erythrocytapheresis for chronic transfusion therapy in sickle cell disease: survey of current practices and review of the literature |
| Q90461871 | Evaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed by Newborn Screening: A Real-World Nation-Wide Study in France |
| Q35999807 | Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia |
| Q40229173 | Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). |
| Q45874514 | Fetal haemoglobin induction in sickle cell disease |
| Q36155283 | Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia |
| Q90602349 | Genetic, laboratory and clinical risk factors in the development of overt ischemic stroke in children with sickle cell disease |
| Q50223743 | Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion |
| Q90332496 | Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics |
| Q47740914 | How I manage sickle cell patients with high transcranial doppler results. |
| Q39179372 | How we manage iron overload in sickle cell patients |
| Q54735877 | Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. |
| Q90623352 | Hydroxycarbamide and white matter integrity in pediatric sickle cell disease: Commentary to accompany: Hydroxycarbamide treatment in children with sickle cell anaemia is associated with more intact white matter integrity: a quantitative MRI study |
| Q39412777 | Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. |
| Q38692796 | Hydroxyurea (hydroxycarbamide) for sickle cell disease. |
| Q61908540 | Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa |
| Q36780129 | Hydroxyurea for abnormal TCDs: safe to switch? |
| Q46853675 | Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey. |
| Q89112415 | Incomplete implementation of guideline-based stroke prevention therapy in sickle cell disease |
| Q52721996 | Inflammation in sickle cell disease. |
| Q36370980 | Interventions for preventing silent cerebral infarcts in people with sickle cell disease. |
| Q50204137 | Is transplantation an alternative to the transfusional impasse in sickle cell disease? |
| Q45953571 | Kidney function of transfused children with sickle cell anemia: Baseline data from the TWiTCH study with comparison to non-transfused cohorts. |
| Q39041106 | Knowledge insufficient: the management of haemoglobin SC disease |
| Q64108860 | Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France |
| Q89777633 | Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease |
| Q58765141 | Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings |
| Q49338284 | Lower Transcranial Doppler Flow Velocities in Sickle Cell Anemia Patients on Hydroxyurea: Myth or Fact |
| Q90029424 | Measuring success: utility of biomarkers in sickle cell disease clinical trials and care |
| Q92914442 | Mechanisms of haemolysis-induced kidney injury |
| Q36913577 | Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication |
| Q60923179 | NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE |
| Q38597215 | Neurologic complications of sickle cell disease in Africa: A systematic review and meta-analysis |
| Q37143296 | New insights into sickle cell disease: mechanisms and investigational therapies |
| Q47581095 | Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease. |
| Q59756229 | Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California |
| Q37563797 | PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE. |
| Q57452740 | Pathophysiology of Sickle Cell Disease |
| Q38814652 | Pediatric sickle cell disease: past successes and future challenges |
| Q39340714 | Prasugrel hydrochloride for the treatment of sickle cell disease |
| Q52905416 | Preventing delayed hemolytic transfusion reactions in sickle cell disease. |
| Q39027875 | Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative |
| Q48021426 | Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa |
| Q92616034 | Red Blood Cells: Exchange, Transfuse, or Deplete |
| Q57688958 | Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews |
| Q47236829 | Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia. |
| Q39494212 | Reticulocyte count is the most important predictor of acute cerebral ischemia and high-risk transcranial Doppler in a newborn cohort of 395 children with sickle cell anemia |
| Q38732049 | Sickle Cell Disease and Stroke: Diagnosis and Management |
| Q52354763 | Sickle cell disease. |
| Q52795486 | Sickle cell disease. |
| Q53774753 | Sickle cell disease. |
| Q42374716 | Sickle cell disease: Status with particular reference to India |
| Q48174073 | Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease |
| Q40411281 | Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation |
| Q30395921 | Sickle cell disease: when and how to transfuse |
| Q33808268 | Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia |
| Q42292910 | Stroke in a Child with Hemoglobin SC Disease: A Case Report Describing use of Hydroxyurea after Transfusion Therapy |
| Q53102076 | Stroke recurrence in adult sickle cell patients: it is time for action! |
| Q93369984 | Surgical Revascularization for Pediatric Patients with Sickle Cell Disease and Moyamoya Disease in the Prevention of Ischemic Strokes: A Single-Center Case Series and a Systematic Review |
| Q91716403 | Targeted Hydroxyurea Education after an Emergency Department Visit Increases Hydroxyurea Use in Children with Sickle Cell Anemia |
| Q92619798 | The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease |
| Q39395228 | The cause of the stroke: a diagnostic uncertainty |
| Q92151287 | The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis |
| Q41118652 | The significance of inadequate transcranial Doppler studies in children with sickle cell disease. |
| Q53977229 | The trials and tribulations of chronic transfusion in pediatric sickle cell disease: progress from STOP to TWiTCH? |
| Q44223235 | Therapeutic advances in sickle cell disease in the last decade |
| Q38953349 | Transcranial doppler re-screening of subjects who participated in STOP and STOP II. |
| Q55073506 | Transfusion in Haemoglobinopathies: Review and recommendations for local blood banks and transfusion services in Oman. |
| Q58415854 | Treating sickle cell anaemia: the TWiTCH trial |
| Q88272672 | Treating sickle cell anaemia: the TWiTCH trial |
| Q90751656 | Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study |
| Q38806417 | Update on sickle cell disease |
| Q52722003 | Vascular complications of sickle cell disease. |
| Q90224995 | Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease |
Search more.